Aniracetam vs NSI-189

Mechanism

Potent positive allosteric modulator of AMPA receptors with 5-10x the potency of piracetam, slowing both channel closing rate and microscopic desensitization rates. Also modulates metabotropic glutamate receptors (mGluRs), activates nicotinic acetylcholine receptors, and indirectly boosts dopaminergic and serotonergic neurotransmission, conferring anxiolytic properties.

Standard Dosing

750-1500 mg/day divided into 2-3 doses

Timing

With fat-containing meals (fat-soluble compound; bioavailability increases significantly with dietary fat)

Cycle Duration

Cycles of 8-12 weeks on, 4 weeks off

Side Effects

• Headache (choline depletion)
• GI discomfort
• Restlessness
• Insomnia if taken late

Contraindications

• Severe hepatic impairment (hepatically metabolized)
• Known hypersensitivity to racetams

Best Stacking Partners

Mechanism

Benzylpiperizine-aminopyridine compound that stimulates neurogenesis of human hippocampus-derived neural stem cells in vitro and increases hippocampal volume in vivo. Mechanism is independent of serotonin or norepinephrine reuptake inhibition — fundamentally distinct from traditional antidepressants. Activates the TrkB receptor (BDNF receptor) and downstream Akt/PI3K signaling pathways to promote synaptic plasticity, long-term potentiation, and neuronal survival. Enhances BDNF expression in hippocampal subregions critical for memory consolidation and mood regulation. Originally developed as ALTO-100 (Alto Neuroscience) for treatment-resistant depression with cognitive impairment.

Standard Dosing

40 mg once daily (for educational context — investigational compound, not approved for any indication)

Timing

Once daily, time of day not definitively established from clinical data. With or without food.

Cycle Duration

Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable.

Side Effects

• Headache
• GI discomfort
• Dizziness
• Somnolence
• Dry mouth
• Generally well-tolerated in Phase 1b and Phase 2 trials

Contraindications

• Pregnancy and lactation (no safety data; neurogenic compounds carry theoretical teratogenic risk)
• History of brain tumors (neurogenic stimulation could theoretically promote growth — speculative)
• No regulatory approval for any indication — investigational use only

Best Stacking Partners